Additional efforts to test the combination of olaparib and AZD6738 is underway in phase II trial in IDH1- and IDH2-mutant cholangiocarcinoma and solid tumors, led by LoRusso and colleagues at our institution (NCT03878095). This evidence concerns the gene IDH2 and cholangiocarcinoma.